Reducing the Health Burden of HPV Infection Through Vaccination

Soper, David

doi:https://doi.org/10.1155/IDOG/2006/83084

Infectious Diseases in Obstetrics and Gynecology

On this page

Abstract References Copyright Related Articles

Special Issue

CME Supplement: Recent Advances in the Prevention of Cervical Cancer and Other Human Papillomavirus Related Diseases

View this Special Issue

Clinical Study | Open Access

Volume 2006 | Article ID 083084 | https://doi.org/10.1155/IDOG/2006/83084

Reducing the Health Burden of HPV Infection Through Vaccination

David Soper¹

Received18 Aug 2005

Accepted20 Sept 2005

Published30 Jan 2006

Abstract

Human papillomavirus (HPV), a sexually transmitted infection and the etiologic cause of genital warts and cervical cancer, is highly prevalent in sexually active men and women. Although cervical screening procedures have significantly reduced the disease burden associated with HPV infection, they are expensive and abnormal results cause significant emotional distress. Therefore, prevention may be an effective strategy for reducing the economic, psychosocial, and disease burden of HPV infection. Multivalent vaccines are now in clinical development. A bivalent vaccine that protects against HPV 16 and 18, and a quadrivalent vaccine which protects against HPV types 6, 11, 16, and 18, have been shown to significantly reduce the occurrence of incident and persistent HPV infections in phase 2 clinical trials; phase 3 trials are currently underway. HPV vaccines will be most effective when administered prior to initiation of sexual activity, and vaccination campaigns should aggressively target preadolescent and adolescent populations.

References

W Jr Cates, “Estimates of the incidence and prevalence of sexually transmitted diseases in the United States. American Social Health Association Panel,” Sexually Transmitted Diseases, vol. 26, no. 4 suppl, pp. S2–S7, 1999.
View at: Google Scholar
H Weinstock, S Berman, and W Jr Cates, “Sexually transmitted diseases among American youth: incidence and prevalence estimates, 2000,” Perspectives on Sexual and Reproductive Health, vol. 36, no. 1, pp. 6–10, 2004.
View at: Google Scholar
R D Burk, P Kelly, J Feldman et al., “Declining prevalence of cervicovaginal human papillomavirus infection with age is independent of other risk factors,” Sexually Transmitted Diseases, vol. 23, no. 4, pp. 333–341, 1996.
View at: Google Scholar
N Muñoz, F X Bosch, S de Sanjosé et al., “Epidemiologic classification of human papillomavirus types associated with cervical cancer,” The New England Journal of Medicine, vol. 348, no. 6, pp. 518–527, 2003.
View at: Google Scholar
C L Peyton, P E Gravitt, W C Hunt et al., “Determinants of genital human papillomavirus detection in a US population,” The Journal of Infectious Diseases, vol. 183, no. 11, pp. 1554–1564, 2001.
View at: Google Scholar
D R Brown, J M Schroeder, J T Bryan, M H Stoler, and K H Fife, “Detection of multiple human papillomavirus types in Condylomata acuminata lesions from otherwise healthy and immunosuppressed patients,” Journal of Clinical Microbiology, vol. 37, no. 10, pp. 3316–3322, 1999.
View at: Google Scholar
L A Koutsky, D A Galloway, and K K Holmes, “Epidemiology of genital human papillomavirus infection,” Epidemiologic Reviews, vol. 10, pp. 122–163, 1988.
View at: Google Scholar
D M Harper, “Why am I scared of HPV?,” CA: A Cancer Journal for Clinicians, vol. 54, no. 5, pp. 245–247, 2004.
View at: Google Scholar
J M Walboomers, M V Jacobs, M M Manos et al., “Human papillomavirus is a necessary cause of invasive cervical cancer worldwide,” The Journal of Pathology, vol. 189, no. 1, pp. 12–19, 1999.
View at: Google Scholar
C Ley, H M Bauer, A Reingold et al., “Determinants of genital human papillomavirus infection in young women,” Journal of the National Cancer Institute, vol. 83, no. 14, pp. 997–1003, 1991.
View at: Google Scholar
G Y Ho, R Bierman, L Beardsley, C J Chang, and R D Burk, “Natural history of cervicovaginal papillomavirus infection in young women,” The New England Journal of Medicine, vol. 338, no. 7, pp. 423–428, 1998.
View at: Google Scholar
J W Sellors, T L Karwalajtys, J Kaczorowski et al., “Incidence, clearance and predictors of human papillomavirus infection in women,” CMAJ: Canadian Medical Association Journal, vol. 168, no. 4, pp. 421–425, 2003.
View at: Google Scholar
R D Burk, G Y Ho, L Beardsley, M Lempa, M Peters, and R Bierman, “Sexual behavior and partner characteristics are the predominant risk factors for genital human papillomavirus infection in young women,” The Journal of Infectious Diseases, vol. 174, no. 4, pp. 679–689, 1996.
View at: Google Scholar
L E Manhart and L A Koutsky, “Do condoms prevent genital HPV infection, external genital warts, or cervical neoplasia? A meta-analysis,” Sexually Transmitted Diseases, vol. 29, no. 11, pp. 725–735, 2002.
View at: Google Scholar
C J Hogewoning, M C Bleeker, and A J van den Brule, “Condom use promotes regression of cervical intraepithelial neoplasia and clearance of human papillomavirus: a randomized clinical trial,” International Journal of Cancer, vol. 107, no. 5, pp. 811–816, 2003.
View at: Google Scholar
R P Insinga, A G Glass, and B B Rush, “The health care costs of cervical human papillomavirus—related disease,” American Journal of Obstetrics and Gynecology, vol. 191, no. 1, pp. 114–120, 2004.
View at: Google Scholar
H W Chesson, J M Blandford, T L Gift, G Tao, and K L Irwin, “The estimated direct medical cost of sexually transmitted diseases among American youth, 2000,” Perspectives on Sexual and Reproductive Health, vol. 36, no. 1, pp. 11–19, 2004.
View at: Google Scholar
J Zhou, X Y Sun, D J Stenzel, and I H Frazer, “Expression of vaccinia recombinant HPV 16 L1 and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virion-like particles,” Virology, vol. 185, no. 1, pp. 251–257, 1991.
View at: Google Scholar
M E Hagensee, N Yaegashi, and D A Galloway, “Self-assembly of human papillomavirus type 1 capsids by expression of the L1 protein alone or by coexpression of the L1 and L2 capsid proteins,” Journal of Virology, vol. 67, no. 1, pp. 315–322, 1993.
View at: Google Scholar
J T Schiller and P Davies, “Delivering on the promise: HPV vaccines and cervical cancer,” Nature Reviews. Microbiology, vol. 2, no. 4, pp. 343–347, 2004.
View at: Google Scholar
J A Suzich, S J Ghim, F J Palmer-Hill et al., “Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas,” Proceedings of the National Academy of Sciences of the United States of America, vol. 92, no. 25, pp. 11553–11557, 1995.
View at: Google Scholar
K U Jansen, M Rosolowsky, L D Schultz et al., “Vaccination with yeast-expressed cottontail rabbit papillomavirus (CRPV) virus-like particles protects rabbits from CRPV-induced papilloma formation,” Vaccine, vol. 13, no. 16, pp. 1509–1514, 1995.
View at: Google Scholar
D V Pastrana, W C Vass, D R Lowy, and J T Schiller, “NHPV16 VLP vaccine induces human antibodies that neutralize divergent variants of HPV16,” Virology, vol. 279, no. 1, pp. 361–369, 2001.
View at: Google Scholar
D Nardelli-Haefliger, D Wirthner, J T Schiller et al., “Specific antibody levels at the cervix during the menstrual cycle of women vaccinated with human papillomavirus 16 virus-like particles,” Journal of the National Cancer Institute, vol. 95, no. 15, pp. 1128–1137, 2003.
View at: Google Scholar
C D Harro, Y Y Pang, R B Roden et al., “Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine,” Journal of the National Cancer Institute, vol. 93, no. 4, pp. 284–292, 2001.
View at: Google Scholar
L A Koutsky, K A Ault, C M Wheeler et al., “A controlled trial of a human papillomavirus type 16 vaccine,” The New England Journal of Medicine, vol. 347, no. 21, pp. 1645–1651, 2002.
View at: Google Scholar
D R Brown, J T Bryan, J M Schroeder et al., “Neutralization of human papillomavirus type 11 (HPV-11) by serum from women vaccinated with yeast-derived HPV-11 L1 virus-like particles: correlation with competitive radioimmunoassay titer,” The Journal of Infectious Diseases, vol. 184, no. 9, pp. 1183–1186, 2001.
View at: Google Scholar
K A Ault, A R Giuliano, R P Edwards et al., “A phase I study to evaluate a human papillomavirus (HPV) type 18 L1 VLP vaccine,” Vaccine, vol. 22, no. 23-24, pp. 3004–3007, 2004.
View at: Google Scholar
K H Fife, C M Wheeler, L A Koutsky et al., “Dose-ranging studies of the safety and immunogenicity of human papillomavirus Type 11 and Type 16 virus-like particle candidate vaccines in young healthy women,” Vaccine, vol. 22, no. 21-22, pp. 2943–2952, 2004.
View at: Google Scholar
D M Harper, E L Franco, C M Wheeler et al., “Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial,” The Lancet, vol. 364, no. 9447, pp. 1757–1765, 2004.
View at: Google Scholar
L L Villa, R L Costa, C A Petta et al., “Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial,” The Lancet Oncology, vol. 6, no. 5, pp. 271–278, 2005.
View at: Google Scholar
F E Skjeldestad, “ FUTURE II steering committee. Prophylactic Quadrivalent Human Papillomavirus (HPV) (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine (Gardasil) Reduces Cervical Intraepithelial Neoplasia (CIN) 2/3 Risk,” in Infectious Disease Society of America 43rd Annual Meeting, San Francisco, Calif, 2005, Abstract LB-8a. Available at: http://www.idsociety.org/Template.cfm?Section=Program2&CONTENTID=14108&TEMPLATE=/ContentManagement/ContentDisplay.cfm. Accessed at: January 16, 2006.
View at: Google Scholar
G D Sanders and A V Taira, “Cost-effectiveness of a potential vaccine for human papillomavirus,” Emerging Infectious Diseases, vol. 9, no. 1, pp. 37–48, 2003.
View at: Google Scholar
A V Taira, C P Neukermans, and G D Sanders, “Evaluating human papillomavirus vaccination programs,” Emerging Infectious Diseases, vol. 10, no. 11, pp. 1915–1923, 2004.
View at: Google Scholar
J P Hughes, G P Garnett, and L A Koutsky, “The theoretical population-level impact of a prophylactic human papillomavirus vaccine,” Epidemiology, vol. 13, no. 6, pp. 631–639, 2002.
View at: Google Scholar
H Baer, S Allen, and L Braun, “Knowledge of human papillomavirus infection among young adult men and women: implications for health education and research,” Journal of Community Health, vol. 25, no. 1, pp. 67–78, 2000.
View at: Google Scholar
B Holcomb, J M Bailey, K Crawford, and M T IV Ruffin, “Adults' knowledge and behaviors related to human papillomavirus infection,” The Journal of the American Board of Family Practice, vol. 17, no. 1, pp. 26–31, 2004.
View at: Google Scholar
M Pitts and T Clarke, “Human papillomavirus infections and risks of cervical cancer: what do women know?,” Health Education Research, vol. 17, no. 6, pp. 706–714, 2002.
View at: Google Scholar
D L Dell, H Chen, F Ahmad, and D E Stewart, “Knowledge about human papillomavirus among adolescents,” Obstetrics & Gynecology, vol. 96, no. 5 pt 1, pp. 653–656, 2000.
View at: Google Scholar

Copyright

Copyright © 2006 David Soper. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

PDF Download Citation Order printed copies

Views

490

Downloads

1160

Citations